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ABSTRACT
Purpose: Statins are widely recognized as hypolipemic drugs, but some studies have observed anti-inflammatory and
immunomodulatory effects, known as pleiotropic. The aims of this work was to study possible anti-inflammatory effects of
simvastatin in abdominal sepsis. Serum pro-inflammatory cytokines and leukocytes count were determined in an experimental
model of abdominal sepsis, using cecal ligation and puncture (CLP) in rats. Methods: Twenty eigth Wistar rats weighing
285±12g were randomly divided in: CLP/Sinvastatin rats (n=7), treated with 10 mg/Kg of oral simvastatin 18 and 2 hs berofe
CLP; CLP/Saline group rats (n=7), treated with oral saline;  group Sham/Simvastatin (n=7), treated with simvastatin, and
group Sham/Saline (n=7), treated with saline. Serum TNF-α, IL-1β and IL-6 by ELISA and total leukocytes, neutrophils,
lymphocytes, and eosinophils were determined 24 hs after CLP. ANOVA and Tukey test were used considering significant
p<0.05.  Results: It was demonstrated that serum TNF-α, IL-1β and IL-6 were respectively 364,8±42pg/mL; 46,3±18pg/mL
and 28,4±13pg/mL in CLP/Sinvastatin rats, significantly lower (p<0.05) than in group CLP/Saline (778,5±86pg/ml; 176,9±46pg/
ml; 133,6±21 pg/ml, respectively). The same results were observed in total leukocytes and neutrophils counts. Conclusion:
These results clearly demonstrate that simvastatin is an effective agent that reduces cytokines levels and leukocyte count
in sepsis, independently of its well-known lipid-lowering effects. Thus, HMG-CoA reductase inhibitors like simvastatin
have important anti-inflammatory effects in abdominal sepsis in rats.
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RESUMO
Objetivo: As estatinas são agentes reconhecidamente hipolipemiantes. Vários estudos têm revelado que eles têm ações
pleiotrópicas, como antiinflamatória e imunomoduladora. Tentando-se entender o papel antiinflamatório da sinvastatina
na sepse, foram analisados os níveis de citocinas pró-inflamatórias e contagem de leucócitos em modelo de sepse abdominal
por ligadura e punção do ceco (LPC) em ratos. Métodos: Foram utilizados 28 ratos Wistar pesando 285±12g, assim divididos:
grupo sepse (n=14), submetidos a LPC e grupo sham (n=14), submetidos a laparotomia e manipulação suave do ceco. No
grupo LPC/sinvastatina (n=7) os ratos receberam 10mg/kg de sinvastatina via oral 18 e 2 horas antes da LPC e no grupo
LPC/salina (n=7) os ratos receberam injeção oral de solução salina 0,9 %. Os animais dos grupos sham/sinvastatina (n=7)
e sham/salina (n=7) receberam o mesmo tratamento. Dosagem de  TNF-α, IL-1β e IL-6 por ELISA e contagem de leucócitos
totais, neutrófilos, linfócitos e eosinófilos foram realizadas em todos os animais. Análise estatística foi feita pelo ANOVA
e teste de Tukey, com significância p<0,05.  Resultados: Ficou demonstrado que as dosagens de TNF-α, IL-1β e IL-6
atingiram valores de 364,8±42pg/ml; 46,3±18pg/ml e 28,4±13pg/ml no grupo submetido à sepse e tratados com sinvastatina,
significantemente mais baixos do que no grupo sepse não tratados (778,5±86pg/ml; 176,9±46pg/ml; 133,6±21 pg/ml,
respectivamente). O mesmo ocorreu na contagem de leucócitos totais e neutrófilos. Conclusão: A sinvastatina mostrou
ação anti-inflamatória em ratos Wistar, diminuiu níveis de citocinas e  leucócitos, sugerindo uso potencial na prevenção ou
atenuação dos efeitos da sepse abdominal.
Descritores: Estatina. Inflamação. Sepse abdominal. Rato Wistar. Citocinas. Leucócitos.
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Introduction
Statins are powerful hypolipemic drugs with pleiotropic
effects and have been shown to improve survival in the
primary and secondary prevention of atherosclerosis in
numerous large randomized clinical trials1,2. By inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase and the mevalonate pathway to cholesterol,
statins reduce not only cholesterol but also the production
of several of its nonsteroidal isoprenoid precursor
intermediates3, which are necessary to membrane anchor
proteins critical to the binding of signaling proteins involved
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Surgical models
Animals were fasted 12 hr before the experiment and
anesthetized with  intramuscular injection of 0.1 mL/100g weight,
of a solution prepared with 1.0 mL of ketamine (50mg/mL) and
1.0 mL of xilazine (20mg/mL). They breathed spontaneously
throughout the procedures. After shaving, the abdominal skin
was disinfected with 70% alcohol. All procedures were
performed under sterile conditions. Midline laparotomy (3 cm)
and gentle manipulation of cecum was performed in the sham
group. In the sepsis group the cecum was exposed, ligated
with silk 2-0, one cm distally to the ileocecal valve to avoid
intestinal obstruction. Four punctures were performed with a
22-gauge needle, squeezed gently to force out a small amount
of feces, and then it was returned to the abdominal cavity. The
abdominal incision was closed with 4-0 nylon sutures. All
animals were observed for 24 hours, weighed again and
anesthetized with ketamine  intramuscular (50 mg/kg). Thorax
was opened, blood was collected by cardiac puncture for
cytokine assay and leukocyte count.
Experimental design
FIGURE 1 - Experimental design: 14 rats were divided into
group CLP/sepsis treated with simvastatin
(CLP/Simvastatin n=7) and with saline (CLP/
saline n=7). In group sham (n=14), rats were
treated with simvastatin (Sham/Simvastatin
n=7) and with saline (Sham/Saline n=7).
Cytokine assays
Blood samples were used for measurement of tumor
necrosis factor-alfa (TNFα),  interleukin-1β (IL-1β) and
interleukin-6 (IL-6) , determined using enzyme-linked
immunoassay kits (all from PeproTech, Rocky Hill, NJ, USA),
according to the manufacturer’s recommended protocols.
The fluorescence was measured by a Bio-Tec Instruments
EL 808 ultra microplate reader, using  KC4-V3.0 analysis
software. Sensitivity of detection was 20 pg/ml for cytokines.
Leukocyte count
Whole blood was collected by cardiac puncture for
leukocyte cell counts  using a commercially available
automated cell counter (Abbott Cell-Dyn 3500R- CD 3500
5L, USA).
Statistical analysis
Data are reported as mean± SEM. Statistical analyses
were conducted with commercially available software SPSS
14.0.1 for Windows. Values of p were reported in cases in which
in various cell functions. Several cellular and animal models
demonstrate the pleiotropic activity of statins, including
antiinflammatory and antioxidative properties,
immunomodulatory effects, improvement in endothelial
function, reduction in blood thrombogenicity, and increased
nitric oxide (NO) bioavailability. Some or all of these effects
may account for a substantial potential impact of statins on
the complex pro and anti-inflammatory sequence of events
occurring during sepsis. Extensive research has been
invested in the last 2 decades and  sepsis remains the leading
cause of death among patients treated in intensive care
units, with mortality rates ranging between 30% and 70%4,5.
Sepsis is generally viewed as a disease aggravated by the
inappropriate and inefficient immune response encountered
in the affected individual.  Corticosteroids6,7, activated
protein C8,  tumor necrosis factor (TNF) antagonists9,
interleukin-1 receptor antagonists10, anti-endotoxin
antibodies11, and ibuprofen12 have all been evaluated in a
clinical setting, with improved outcome demonstrated
recently for activated protein C. HMG-CoA reductase
inhibitors (statins) such as simvastatin have been shown
to exhibit important immunomodulatory effects independent
of lipid lowering13. These pleiotropic effects have been
demonstrated to include anti-inflammatory actions14,
improvement of endothelial and microvascular function, and
modulation of endothelial nitric oxide synthase (eNOS)15.
However, statins have thus far not been used to treat severe
inflammatory states such as sepsis. Knowing that infection
is an important risk factor to operated people and that statins
have anti-inflammatory and antioxidant properties, we
hypothesized that simvastatin pretreatment would be
protective against abdominal sepsis in rats.
Methods
The experimental protocol was approved by the
Research Ethics Committee of the University Hospital-
UFRN, Brazil. Animals were handled in accordance with the
Guide for the Care and Use of Laboratory Animals, US
National Research Council, 1996.
Animals
Wistar rats weighing 285??6g were used. Rats were
housed in polypropilene cages and maintained under
controlled temperature conditions on a 12h light-dark cycle
and allowed ad libitum access to commercially available rat
chow (Labina, Purina®) and water.
Experimental design
A total of 28 Wistar rats were randomly distributed
into the following four groups: In the sepsis group (n=14),
a half of the (CLP/Sinvastatin) rats (n=7) received 10 mg/Kg
of simvastatin microemulsion via gavage, 18 and 2 hours
before cecal ligation and puncture (CLP). The remaining
(CLP/Saline group) rats (n=7) were treated with oral injection
of saline 18 and 2 hs before CLP. In the group sham, 7 rats
were treated with simvastatin (Sham/Simvastatin group) and
7 with saline (Sham/Saline group) as sepsis group.
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tests were performed. A value of p<0.05 was considered
significant.  ANOVA with  post hoc Tukey’s test was used to
compare the groups.
Results
All the animals survived to experiments. The results were
tabulated and exhibited as mean±SD. Leukocyte counts
obtained at 24 hours after CLP confirmed significant lowering
of WBC  and neutrophils in simvastatin treated (CLP/
simvastatin) rats of the sepsis group, when compared with the
untreated (CLP/saline) rats (p<0.05), as can be seen on Table 1.
To address possible changes in WBC, neutrophils, limphocytes
and eosinophils, secondary to the sham operation, we studied
the cells count. No difference was  observed comparing the
simvastatin (Sham/Simvastatim) treated and saline (Sham/
Saline) treated rats (p>0.05). To investigate the effects of sepsis
and simvastatin treatment on cytokines, serum was isolated
from all groups of rats (CLP/saline, CLP-simvastatin, sham/
saline, and sham/simvastatin) and subjected to ELISA assay.
The levels of  TNFα, IL-1β  and IL-6 from CLP/simvastatin
treated rats were significantly decreased compared with that
of CLP/saline rats (Table 2). Cytokines from CLP animals, treated
or untreated with simvastatin, displayed an increased levels
compared with the sham operated rats (p>0.05), as observed in
Table 2.  No difference was detected among the values of
cytokines (pg/mL) from sham rats treated with simvastatin and
sham-operated rats treated with saline. (p>0.05). This
observation indicates that the simvastatin has interference
with the expression of cytokines in septic animals, but not in
the absence of sepsis.
TABLE 1 - Number of WBC and percent of neutrophils, lymphocytes and eosinophils from the studied rats.
WBC/µL)*(1) Neutrophils (%)*(1) Lymphocytes (%)*(2) Eosinophils(%)*(2)
CLP/Saline 9,46 ± 1,26ab 76,37 ± 6,57abc 16,36 ± 4,58a 0,39 ± 0,42a
CLP/Simvastatin 6,72 ± 0,39ab 56,50 ± 7,08a 37,03 ± 10,94a 0,57 ± 0,59a
Sham/Saline 4,68 ± 0,56a 57,17 ± 6,60b 34,14 ± 9,26b 5,41 ± 5,16b
Sham/Simvastatin 4,32 ± 0,53b 57,10 ± 8,52c 30,27 ± 8,55b 5,68 ± 5,78b
*Mean ± Standard Deviation; CLP, cecal ligation and puncture.; WBC, white blood cell.
(1) Values followed by the same letter differ among them, considering p<0.05 by Tukey test.
(2) Values followed by the same letter do not differ among them, considering p<0.05 by Tukey test.
                 Leukocytes
Groups
TABLE 2 - Values of TNFα, IL-1β e IL-6 from the studied rats
Groups TNFα (pg/ml) IL-1β (pg/ml) IL-6 (pg/ml)
CLP/Saline 778,5 ± 86a 176,9 ± 46a 133,6 ± 21a
CLP/Simvastatin 364,8 ± 42a   66,3 ± 18a   58,4 ± 13a
Sham/Saline   31,3 ± 6,1   28,1 ± 4   29,8 ± 2
Sham/Sinvastatin   20,7 ± 4,5a   27,3 ± 5a   23,1 ± 4a
*Mean ± Standard Deviation; CLP, cecal ligation and puncture.
(1) Values followed by the same letter differ among them, considering p<0.05 by Tukey test.
(2) Values followed by the same letter do not differ among them, considering p<0.05 by Tukey test.
Discussion
The 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA)
reductase inhibitor class of drugs (statins) was introduced
into clinical practice in the 1980s. They have become the most
widely used drugs for lowering plasma cholesterol. Patients
with coronary artery disease, highrisk elderly patients, and
those having major surgery, benefit from statin therapy16-19.
Some works have been presenting several effects (anti-
inflammatory, antitrombotic, immunomodulator, etc) of the
statins, those denominated together as pleiotropic effects, that
do not depend on the reductions in the cholesterol levels20-
23,25. Enlarging the classic use of the statins, the challenge in
subject is to evidence other actions of these molecules seen
that, many pleiotropic effects have been told, as well as anti-
inflammatory properties, action in the endotelial function and
benefits in the hemostasia23-25,.   In the best attempt to
understand the anti-inflammatory effects of the simvastatin in
the sepsis, rats were previously treated with this drug and
submitted to the model of abdominal sepsis by CLP. The levels
of pro-inflammatory cytokines and counting of total
leukocytes, neutrophils, lymphocytes and eosinphils were
analyzed, considering that they are factors that participate
actively of the inflammatory process. The experimental model
is one of the main means to study sepsis of abdominal origin.
The study of the sepsis in experimental models can be driven
with administration lipopolissacárides (LPS) intravascular,
bacterial peritonitis induced by introduction of feces or bacteria
in the peritonial cavity, opening of an intestinal segment or
cecal ligation and puncture26,27. The CLP model was adopted
in this work by presenting some advantages, as it is easy
reproducible, simple, it is not necessary the standardization of
an inocule. This is the model that better approaches the human
sepsis. The sepsis is polymicrobial and simulates the perforated
appendicitis or diverticulitis26. It is believed that this
experimental model is an appropriate study method to evaluate
and to control the septic phenomena from its installation to
the moment of failure of the organs and systems in different
times in this process28. The experimental design of this study
was elaborated in a such way that the evidences of the anti-
inflammatory effect of the sinvastatin in the abdominal sepse
were evaluated in currently used biological models. After the
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statistical treatment of the results, a discerning analysis of
these data resulted in some interesting observations. Except
for the groups without infection (group sham), the  total
leukocytes count indicated an accumulation of these cells as a
consequence of the trauma and ischemia on the tissues.  The
use of simvastatin in the infected rats inhibited the
accumulation of the neutrophils, but not in the absence of
sepsis. On the other hand, it was observed that in the septic
groups, the simvastatin didn’t promote significant alteration
in the lymphocytes and eosinophils counts. In relation to the
cytokines dosages, it was observed that the simvastatin didn’t
result in a significant change in the levels of TNFα, IL-1β and
IL-6 in the sham rats. The abdominal sepsis served to
demonstrate a significant anti-inflammatory effect of
simvastatin. This fact can be corroborated by the significant
reduction of the levels of these cytokines in the infected
animals, when simvastatin was administered. These data
suggest an important relationship between the statin and the
cells of the immune system in the validity of the mechanisms
of repair of the traumatic damage, as well as during the
activation of the monocytes. Therefore, it was demonstrated
in the present work that the serum TNFα, IL-1β, IL-6, total
leukocytes and neutrophils had statistically significant
reduction (p <0,05) in the groups submitted to the sepsis and
treated with simvastatin, compared with those non treated rats.
These data corroborate with the work of Villa et al29, where the
levels of TNF-α, IL-1β and IL-6 became altered in the same
model of CLP polymicrobial abdominal sepsis. Koo et al30
demonstrated in CPL model that the expression of genes for
these cytokines happen during the abdominal sepse, not only
in the intestinal site, but also in other organs. The results
obtained in the present work are also in agreement with those
visualized by Merx et al31. They demonstrated that the
simvastatin, injected 20 hours after CLP in the same
concentration used in the present study (10 mg/mL), increased
the time of survival, as well as it preserved the heart and
hemodinamic functions of the studied rats. In this same work it
was demonstrated in vitro that the monocytes adhesion was
increased in the group sepsis, when compared with the group
sham. The adhesion decreased when these cells were incubated
with simvastatin. The increasing adhesion is an important factor
in the physiopathology of the sepsis. The benefit of the anti-
inflammatory action of the statins was also analyzed by Merx
et al31,32, who studied the effect of the atrovastatin, pravastatin,
simvastatin and fluvastatin in the survival in a CLP model in
murines. The authors demonstrated that the treatment after 6
hours of the induction of the sepse increased the time of
survival of the animals, except the fluvastatin, that didn’t alter
the survival. In the present study we did not find difference in
survival between the groups, because no mortality occurred.
The host reaction to the peritoneal sepsis involves antibodies
production, complement activation, cellular immunity and
bacterial destruction by polymorphonuclear leukocytes and
macrophages33-35. The mechanism of the anti-inflammatory
action of simvastin is not completely elucidated. However,
some hypothesis exist to explain its action. The bacterial toxins
are recognized by a variety of receptors in the monocyte
surface, macrophages and granulocytes. The cytokines (TNF,
IL-1 and IL-6)  increase the expression of adhesion molecules
(selectines and iCAMs) recruiting neutrófilos for the infection
site35. The IL-1 produces several effects similar to the exogen
TNF, as fever, anorexia and hypotension. It also produces
increase in the leukocyte adhesion, bone reabsorption,
inhibition of the lipoprotein-lipase and the synthesis of
collagen36. Great efforts have been used in the attempt of
elucidating the action of the statins in the sepsis, because
there great therapeutic potential37,38. Few clinical studies have
been published recently to support the hypothesis of the
action of therapy with simvastatin in sepse. Almog et al39
performed a prospective observacional cohort study to
determine the impact of pre-treatment with statins in the
occurrence of severe sepse in infected patients. Of the 361
patients with bacterial infection, 82 (23%) had received statins
at least 4 weeks before admission. The mortality tax was low
and it didn’t differ significantly among the 2 groups (3.7% vs
8.6%, P=0.21).  Severe sepsis developed in the 2.4% and 19%,
of the patients respectively, in the group with statin and without
statin. In other retrospective revision of 388 patient with
bacteremia, Liappis et al40 described a significant reduction in
the patients’ mortality when they received statins in the period
of the admission, compared with those without this therapy.
Conclusion
The data of the present study suggest that simvastatin
has potential to attenuate or to prevent the effects of the
abdominal sepsis in rats subjected to cecal ligation and
punture, represented by the reduction of the levels of serum
cytokines, total leukocytes and neutrophils.
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